CCR6 and autoimmune disease: The reduced level of CCL20 upon AEA treatment is of particular interest, given that CCL20 is the major chemokine for Th17 migration to the inflammatory milieu by engaging its receptor CCR6 on the Th17 cell surface, and the CCR6-CCL20 axis is involved in the pathogenesis of various chronic inflammatory and autoimmune diseases (Meitei et al., 2021).